CNS Pharmaceuticals Inc.’s U.S. manufacturer, Pharmaceutics International Inc., has completed the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (GBM), an aggressive form of brain cancer currently considered incurable.   “Completing the manufacturing process for Berubicin in the United States is an essential step in our preparations to file an IND during the fourth quarter of this year,” stated John Climaco, CEO ...